These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27124592)

  • 1. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
    Ali R; Babad J; Follenzi A; Gebe JA; Brehm MA; Nepom GT; Shultz LD; Greiner DL; DiLorenzo TP
    Immunology; 2016 Aug; 148(4):339-51. PubMed ID: 27124592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
    Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
    FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
    Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
    Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visualization of the human CD4⁺ T-cell response in humanized HLA-DR4-expressing NOD/Shi-scid/γc(null) (NOG) mice by retrogenic expression of the human TCR gene.
    Takahashi T; Katano I; Ito R; Ito M
    Biochem Biophys Res Commun; 2015 Jan; 456(1):219-24. PubMed ID: 25462565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.
    Pino S; Brehm MA; Covassin-Barberis L; King M; Gott B; Chase TH; Wagner J; Burzenski L; Foreman O; Greiner DL; Shultz LD
    Methods Mol Biol; 2010; 602():105-17. PubMed ID: 20012395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.
    Ha SP; Klemen ND; Kinnebrew GH; Brandmaier AG; Marsh J; Hangoc G; Palmer DC; Restifo NP; Cornetta K; Broxmeyer HE; Touloukian CE
    J Clin Invest; 2010 Dec; 120(12):4273-88. PubMed ID: 21084750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.
    Babad J; Mukherjee G; Follenzi A; Ali R; Roep BO; Shultz LD; Santamaria P; Yang OO; Goldstein H; Greiner DL; DiLorenzo TP
    Clin Exp Immunol; 2015 Mar; 179(3):398-413. PubMed ID: 25302633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
    Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
    Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells.
    Büchner SM; Sliva K; Bonig H; Völker I; Waibler Z; Kirberg J; Schnierle BS
    Clin Exp Immunol; 2013 Aug; 173(2):355-64. PubMed ID: 23607364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
    Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
    Front Immunol; 2021; 12():686439. PubMed ID: 34616392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
    Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
    PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
    Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
    Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses.
    Yaguchi T; Kobayashi A; Inozume T; Morii K; Nagumo H; Nishio H; Iwata T; Ka Y; Katano I; Ito R; Ito M; Kawakami Y
    Cell Mol Immunol; 2018 Nov; 15(11):953-962. PubMed ID: 29151581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.
    Nervi B; Rettig MP; Ritchey JK; Wang HL; Bauer G; Walker J; Bonyhadi ML; Berenson RJ; Prior JL; Piwnica-Worms D; Nolta JA; DiPersio JF
    Exp Hematol; 2007 Dec; 35(12):1823-38. PubMed ID: 17764813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
    Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
    J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.
    Eguren-Santamaria I; Fernández de Piérola E; Camps G; Martín-Muñoz P; Campos M; Cuculescu D; Aguilera-Buenosvinos I; Rodríguez López I; Salido-Vallejo R; Alexandru R; De Andrea CE; Álvarez-Gigli L; Berraondo P; Melero I; Sanmamed MF
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39244214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
    Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
    Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three humanized mouse models for adoptive T cell transfer.
    Volk A; Hartmann S; Muik A; Geiss Y; Königs C; Dietrich U; von Laer D; Kimpel J
    J Gene Med; 2012 Aug; 14(8):540-8. PubMed ID: 22847974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
    Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
    Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
    Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
    Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.